147 related articles for article (PubMed ID: 36400695)
1. Primary Thromboprophylaxis and the Risk of Venous Thromboembolic Events in Patients With Testicular Germ Cell Tumors Treated With Cisplatinum-Based Chemotherapy.
Terbuch A; Walser G; Stotz M; Gerger A; Posch F; Bauernhofer T
Clin Genitourin Cancer; 2023 Feb; 21(1):24-31. PubMed ID: 36400695
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors.
Bezan A; Posch F; Ploner F; Bauernhofer T; Pichler M; Szkandera J; Hutterer GC; Pummer K; Gary T; Samonigg H; Beyer J; Winder T; Hermanns T; Fankhauser CD; Gerger A; Stotz M
PLoS One; 2017; 12(4):e0176283. PubMed ID: 28430804
[TBL] [Abstract][Full Text] [Related]
3. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).
Tran B; Ruiz-Morales JM; Gonzalez-Billalabeitia E; Patrikidou A; Amir E; Seidel C; Bokemeyer C; Fankhauser C; Hermanns T; Rumyantsev A; Tryakin A; Brito M; Fléchon A; Kwan EM; Cheng T; Castellano D; Garcia Del Muro X; Hamid AA; Ottaviano M; Palmieri G; Kitson R; Reid A; Heng DYC; Bedard PL
Cancer Med; 2020 Jan; 9(1):116-124. PubMed ID: 31715650
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin prophylaxis is not associated with decreased incidence of venous thromboembolism in testicular germ cell tumor patients receiving chemotherapy.
Hapakova N; Chovanec M; Rejlekova K; Kalavska K; Obertova J; Palacka P; De Angelis V; Sycova-Mila Z; Mardiak J; Mego M
Neoplasma; 2022 Mar; 69(2):456-463. PubMed ID: 35068164
[TBL] [Abstract][Full Text] [Related]
5. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy.
Srikanthan A; Tran B; Beausoleil M; Jewett MA; Hamilton RJ; Sturgeon JF; O'Malley M; Anson-Cartwright L; Chung PW; Warde PR; Winquist E; Moore MJ; Amir E; Bedard PL
J Clin Oncol; 2015 Feb; 33(6):582-7. PubMed ID: 25605848
[TBL] [Abstract][Full Text] [Related]
6. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.
Fankhauser CD; Tran B; Pedregal M; Ruiz-Morales JM; Gonzalez-Billalabeitia E; Patrikidou A; Amir E; Seidel C; Bokemeyer C; Hermanns T; Rumyantsev A; Tryakin A; Brito M; Fléchon A; Kwan EM; Cheng T; Castellano D; Del Muro XG; Hamid AA; Ottaviano M; Palmieri G; Kitson R; Reid A; Heng DYC; Bedard PL; Sweeney CJ; Connors JM
Eur Urol Focus; 2021 Sep; 7(5):1130-1136. PubMed ID: 33032968
[TBL] [Abstract][Full Text] [Related]
7. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.
Gizzi M; Oberic L; Massard C; Poterie A; Le Teuff G; Loriot Y; Albiges L; Baciarello G; Michels J; Bossi A; Blanchard P; Escudier B; Fizazi K
Eur J Cancer; 2016 Dec; 69():151-157. PubMed ID: 27821318
[TBL] [Abstract][Full Text] [Related]
8. Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy.
Brown LC; Robinson M; McCormack M; Steuerwald N; Symanowski J; Sha W; Bose R; Neelands B; Akinyelu T; Livasy C; Li W; Haynes N; Hamilton A; Smith M; Clark PE; Patel J; Burgess EF
Clin Genitourin Cancer; 2024 Jun; 22(3):102086. PubMed ID: 38697880
[TBL] [Abstract][Full Text] [Related]
9. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
10. Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study.
Haugnes HS; Negaard HF; Jensvoll H; Wilsgaard T; Tandstad T; Solberg A
Eur Urol Open Sci; 2021 Oct; 32():19-27. PubMed ID: 34667955
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
[TBL] [Abstract][Full Text] [Related]
12. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
13. Predictors of thrombosis in testicular cancer during platinum-based chemotherapy.
Paffenholz P; Grein K; Heidegger I; Nestler T; Grabbert M; Salem J; Hellmich M; Pfister D; Heidenreich A
World J Urol; 2019 Sep; 37(9):1907-1916. PubMed ID: 30547197
[TBL] [Abstract][Full Text] [Related]
14. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD004318. PubMed ID: 31449321
[TBL] [Abstract][Full Text] [Related]
15. Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study.
Robinson AG; Wei X; Karim S; Raphael MJ; Bedard PL; Booth CM
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e188-e193. PubMed ID: 32387044
[TBL] [Abstract][Full Text] [Related]
16. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
17. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021.
Fankhauser CD; Oldenburg J; Albers P; Algaba F; Bokemeyer C; Boormans JL; Fischer S; Fizazi K; Gremmels H; Mayor de Castro J; Janisch F; Muilwijk T; Leão R; Nicol D; Nicolai N; Tandstad T; Pilar Laguna M
Eur Urol; 2021 Jul; 80(1):4-6. PubMed ID: 33722419
[TBL] [Abstract][Full Text] [Related]
18. A Single-Center Comparison of Extended and Restricted THROMBOPROPHYLAXIS with LMWH after Metabolic Surgery.
Leeman M; Biter LU; Apers JA; Birnie E; Verbrugge S; Verhoef C; Dunkelgrun M
Obes Surg; 2020 Feb; 30(2):553-559. PubMed ID: 31641983
[TBL] [Abstract][Full Text] [Related]
19. Implementation of routine venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
McLaughlin HD; Greco P; Straubhar AM; Rolston A; McCool K; Brackmann M; Siedel JH; McLean K; Reynolds RK; Uppal S
Gynecol Oncol; 2023 Nov; 178():89-95. PubMed ID: 37832182
[TBL] [Abstract][Full Text] [Related]
20. The risk of venous thromboembolism in surgically treated hip fracture: A retrospective cohort study of 5184 patients.
Beauchamp-Chalifour P; Belzile ÉL; Michael R; Langevin V; Gaudreau N; Normandeau N; Bédard L; Pelet S
Orthop Traumatol Surg Res; 2022 Feb; 108(1):103142. PubMed ID: 34775033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
